Department of Sports Dietetics, Poznan University of Physical Education, 61-871, Poznan, Poland.
Sport Sciences-Biomedical Department, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic.
Sci Rep. 2023 May 1;13(1):7081. doi: 10.1038/s41598-023-34343-0.
This double-blind placebo-controlled cross-over study utilized comprehensive monitoring of blood bicarbonate (HCO) kinetics and evaluation of gastrointestinal (GI) upset to determine their impact on an ergogenic potential of sodium bicarbonate (SB) co-ingested with carbohydrate (CHO). Nineteen CrossFit athletes performed 6 bouts of 15 s Wingate Anaerobic Test (WAnT) 90 min post-ingestion of 0.4 g·kg body mass (BM) of SB (SB + CHO treatment) or PLA (PLA + CHO treatment) with 15 g CHO. Blood HCO concentration was evaluated at baseline, 30-, 60-, 75- and 90 min post-ingestion, in between WAnT bouts, and 3 and 45 min post-exercise, while GI upset at 120 min after protocol started. Control (no supplementation; CTRL) procedures were also performed. An effective elevation of extra-cellular buffering capacity was observed 60-90 min post-ingestion of SB + CHO. At mean peak blood HCO, or at start of exercise an increase > 6 mmol·L in HCO was noted in 84% and 52.6% participants, respectively. SB + CHO did not prevent performance decrements in WAnT bouts. There were no significant relationships between changes in blood HCO and WAnTs' performance. Total GI was significantly higher in SB + CHO compared to CTRL, and stomach problems in SB + CHO compared to CTRL and PLA + CHO. There were inverse associations between peak- (p = 0.031; r = - 0.495), average- (p = 0.002; r = - 0.674) and minimum power (p = 0.008; r = - 0.585) and total GI upset, as well as average power and severe GI distress (p = 0.042; r = - 0.471) at SB + CHO. The implemented dose of SB + CHO was effective in improving buffering capacity, but did not prevent decrements in WAnTs' performance. GI side effects were crucial in affecting the ergogenic potential of SB and thus must be insightfully monitored in future studies.
这项双盲安慰剂对照交叉研究利用血液碳酸氢盐（HCO）动力学的综合监测和胃肠道（GI）不适的评估，以确定其对与碳水化合物（CHO）一起摄入的碳酸氢钠（SB）的促能潜力的影响。19 名 CrossFit 运动员在摄入 0.4 g·kg 体重（BM）的 SB（SB+CHO 治疗）或 PLA（PLA+CHO 治疗）后 90 分钟内进行了 6 次 15 秒的 Wingate 无氧测试（WAnT），CHO 为 15 g。在摄入后 30、60、75 和 90 分钟，WAnT 回合之间以及运动后 3 和 45 分钟评估血液 HCO 浓度，在方案开始后 120 分钟评估胃肠道不适。还进行了对照（无补充；CTRL）程序。在摄入 SB+CHO 后 60-90 分钟观察到细胞外缓冲能力的有效升高。在平均峰值血液 HCO 或运动开始时，分别有 84%和 52.6%的参与者 HCO 增加超过 6 mmol·L。SB+CHO 并没有防止 WAnT 回合中的表现下降。血液 HCO 的变化与 WAnTs 表现之间没有显著关系。与 CTRL 相比，SB+CHO 的总胃肠道问题明显更高，与 CTRL 和 PLA+CHO 相比，SB+CHO 的胃部问题更多。峰值（p=0.031；r=-0.495）、平均（p=0.002；r=-0.674）和最小功率（p=0.008；r=-0.585）与总胃肠道不适之间存在反比关系，以及平均功率和严重胃肠道不适（p=0.042；r=-0.471）在 SB+CHO 中。实施的 SB+CHO 剂量有效改善了缓冲能力，但并未防止 WAnTs 表现下降。胃肠道副作用对 SB 的促能潜力至关重要，因此必须在未来的研究中进行深入监测。
